Royalty Pharma plc [RPRX] Is Currently 2.56 below its 200 Period Moving Avg: What Does This Mean?

Royalty Pharma plc [NASDAQ: RPRX] stock went on an upward path that rose over 2.56% on Wednesday, amounting to a one-week price increase of more than 1.38%. The company report on September 6, 2022 that Royalty Pharma to Present at Upcoming Investor Conferences.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:.

Citi’s 17th Annual BioPharma Conference on Thursday, September 8 at 11:20 a.m. ET.

Over the last 12 months, RPRX stock rose by 12.67%. The one-year Royalty Pharma plc stock forecast points to a potential upside of 24.07. The average equity rating for RPRX stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $25.51 billion, with 436.32 million shares outstanding and 323.61 million shares in the current float. Compared to the average trading volume of 1.81M shares, RPRX stock reached a trading volume of 4013053 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Royalty Pharma plc [RPRX]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RPRX shares is $54.34 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RPRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

UBS have made an estimate for Royalty Pharma plc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 14, 2022. While these analysts kept the previous recommendation, Scotiabank raised their target price to Sector Outperform. The new note on the price target was released on May 13, 2022, representing the official price target for Royalty Pharma plc stock. Previously, the target price had yet another raise to $56, while Goldman analysts kept a Buy rating on RPRX stock.

The Average True Range (ATR) for Royalty Pharma plc is set at 0.89, with the Price to Sales ratio for RPRX stock in the period of the last 12 months amounting to 11.29. The Price to Book ratio for the last quarter was 2.99, with the Price to Cash per share for the same quarter was set at 5.50. Price to Free Cash Flow for RPRX in the course of the last twelve months was 255073.44 with Quick ratio for the last quarter at 19.20.

RPRX Stock Performance Analysis:

Royalty Pharma plc [RPRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 1.38. With this latest performance, RPRX shares dropped by -2.50% in over the last four-week period, additionally plugging by 6.50% over the last 6 months – not to mention a rise of 12.67% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RPRX stock in for the last two-week period is set at 44.61, with the RSI for the last a single of trading hit 47.08, and the three-weeks RSI is set at 44.76 for Royalty Pharma plc [RPRX]. The present Moving Average for the last 50 days of trading for this stock 42.72, while it was recorded at 40.55 for the last single week of trading, and 40.88 for the last 200 days.

Insight into Royalty Pharma plc Fundamentals:

Royalty Pharma plc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.20 and a Current Ratio set at 19.20.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RPRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Royalty Pharma plc go to 11.55%.

Royalty Pharma plc [RPRX] Insider Position Details

There are presently around $12,008 million, or 67.60% of RPRX stock, in the hands of institutional investors. The top three institutional holders of RPRX stocks are: MORGAN STANLEY with ownership of 51,543,171, which is approximately -3.733% of the company’s market cap and around 0.10% of the total institutional ownership; FMR LLC, holding 35,953,354 shares of the stock with an approximate value of $1.48 billion in RPRX stocks shares; and VANGUARD GROUP INC, currently with $1.36 billion in RPRX stock with ownership of nearly 3.117% of the company’s market capitalization.

161 institutional holders increased their position in Royalty Pharma plc [NASDAQ:RPRX] by around 44,672,364 shares. Additionally, 126 investors decreased positions by around 22,834,018 shares, while 38 investors held positions by with 223,533,599 shares. The mentioned changes placed institutional holdings at 291,039,981 shares, according to the latest SEC report filing. RPRX stock had 52 new institutional investments in for a total of 2,424,162 shares, while 44 institutional investors sold positions of 6,240,014 shares during the same period.


Please enter your comment!
Please enter your name here